New England Biolabs v F Hoffman-La Roche AG

This case arose between New England Biolabs, an Australian biotechnology company, and F Hoffman-La Roche AG, a Swiss pharmaceutical corporation. The dispute centred on the validity of a patent held by F Hoffman-La Roche AG, which New England Biolabs sought to challenge on the basis that it was not novel, lacked inventive step, and was not sufficiently disclosed. The case was heard in the Federal Court of Australia.

The primary legal issues the court needed to address were whether the patent in question met the statutory requirements for patentability as set out in the Patents Act 1990. Specifically, the court had to determine if the invention claimed by F Hoffman-La Roche AG was novel, involved an inventive step, and was adequately disclosed. Additionally, the court examined whether the patent was open to public use and whether it was relevantly different from prior art.

The court, in its reasoning, found that the invention did not meet the threshold of novelty as it was anticipated by prior art. The court held that the claimed invention was not sufficiently distinct from what was already known in the field. Moreover, the court determined that the patent lacked an inventive step, as the differences between the claimed invention and the prior art were not significant enough to be considered non-obvious. The court also found that the patent specification did not adequately disclose the invention, rendering it insufficiently clear for someone skilled in the art to replicate. Consequently, the court concluded that the patent was invalid on multiple grounds.

In light of the court's findings, the patent held by F Hoffman-La Roche AG was declared invalid. The court made no order regarding the costs of the Commissioner of Patents.